Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 127 entries
Sorted by: Best Match Show Resources per page
Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β.

NPJ primary care respiratory medicine

Pavord ID, Mathieson N, Scowcroft A, Pedersini R, Isherwood G, Price D.
PMID: 29208935
NPJ Prim Care Respir Med. 2017 Dec 05;27(1):65. doi: 10.1038/s41533-017-0063-5.

A correction to this article has been published and is linked from the HTML version of this article.

Cite
Pavord ID, Mathieson N, Scowcroft A, et al. Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β. NPJ Prim Care Respir Med. 2017;27(1):65doi: 10.1038/s41533-017-0063-5.
Pavord, I. D., Mathieson, N., Scowcroft, A., Pedersini, R., Isherwood, G., & Price, D. (2017). Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β. NPJ primary care respiratory medicine, 27(1), 65. https://doi.org/10.1038/s41533-017-0063-5
Pavord, Ian D, et al. "Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β." NPJ primary care respiratory medicine vol. 27,1 (2017): 65. doi: https://doi.org/10.1038/s41533-017-0063-5
Pavord ID, Mathieson N, Scowcroft A, Pedersini R, Isherwood G, Price D. Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β. NPJ Prim Care Respir Med. 2017 Dec 05;27(1):65. doi: 10.1038/s41533-017-0063-5. PMID: 29208935; PMCID: PMC5717274.
Copy Download .nbib Format: NLM
Female reproduction bears no survival cost in captivity for gray mouse lemurs.

Ecology and evolution

Landes J, Henry PY, Hardy I, Perret M, Pavard S.
PMID: 31236213
Ecol Evol. 2019 May 18;9(11):6189-6198. doi: 10.1002/ece3.5124. eCollection 2019 Jun.

The survival cost of reproduction has been revealed in many free-ranging vertebrates. However, recent studies on captive populations failed to detect this cost. Theoretically, this lack of survival/reproduction trade-off is expected when resources are not limiting, but these studies...

Cite
Landes J, Henry PY, Hardy I, et al. Female reproduction bears no survival cost in captivity for gray mouse lemurs. Ecol Evol. 2019;9(11):6189-6198doi: 10.1002/ece3.5124.
Landes, J., Henry, P. Y., Hardy, I., Perret, M., & Pavard, S. (2019). Female reproduction bears no survival cost in captivity for gray mouse lemurs. Ecology and evolution, 9(11), 6189-6198. https://doi.org/10.1002/ece3.5124
Landes, Julie, et al. "Female reproduction bears no survival cost in captivity for gray mouse lemurs." Ecology and evolution vol. 9,11 (2019): 6189-6198. doi: https://doi.org/10.1002/ece3.5124
Landes J, Henry PY, Hardy I, Perret M, Pavard S. Female reproduction bears no survival cost in captivity for gray mouse lemurs. Ecol Evol. 2019 May 18;9(11):6189-6198. doi: 10.1002/ece3.5124. eCollection 2019 Jun. PMID: 31236213; PMCID: PMC6580269.
Copy Download .nbib Format: NLM
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.

The Lancet. Respiratory medicine

Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M.
PMID: 34597534
Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28.

BACKGROUND: Clinical trials have shown treatment benefits of dupilumab in patients with uncontrolled asthma for up to 1 year. This study aimed to evaluate the long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma, as data for...

Cite
Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2021;10(1):11-25doi: 10.1016/S2213-2600(21)00322-2.
Wechsler, M. E., Ford, L. B., Maspero, J. F., Pavord, I. D., Papi, A., Bourdin, A., Watz, H., Castro, M., Nenasheva, N. M., Tohda, Y., Langton, D., Cardona, G., Domingo, C., Park, H. S., Chapman, K. R., Mao, X., Zhang, Y., Khan, A. H., Deniz, Y., Rowe, P. J., Kapoor, U., Khokhar, F. A., Mannent, L. P., Ruddy, M., Laws, E., Amin, N., & Hardin, M. (2022). Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. The Lancet. Respiratory medicine, 10(1), 11-25. https://doi.org/10.1016/S2213-2600(21)00322-2
Wechsler, Michael E, et al. "Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study." The Lancet. Respiratory medicine vol. 10,1 (2022): 11-25. doi: https://doi.org/10.1016/S2213-2600(21)00322-2
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28. PMID: 34597534.
Copy Download .nbib Format: NLM
White blood cells in pregnancy: reference intervals for before and after delivery.

EBioMedicine

Dockree S, Shine B, Pavord S, Impey L, Vatish M.
PMID: 34826802
EBioMedicine. 2021 Nov 23;74:103715. doi: 10.1016/j.ebiom.2021.103715. Epub 2021 Nov 23.

BACKGROUND: White blood cells (WBC) are commonly measured to investigate suspected infection and inflammation in pregnant women, but the pregnancy-specific reference interval is variably reported, increasing diagnostic uncertainty in this high-risk population. It is essential that clinicians can interpret...

Cite
Dockree S, Shine B, Pavord S, et al. White blood cells in pregnancy: reference intervals for before and after delivery. EBioMedicine. 2021;74:103715doi: 10.1016/j.ebiom.2021.103715.
Dockree, S., Shine, B., Pavord, S., Impey, L., & Vatish, M. (2021). White blood cells in pregnancy: reference intervals for before and after delivery. EBioMedicine, 74103715. https://doi.org/10.1016/j.ebiom.2021.103715
Dockree, Samuel, et al. "White blood cells in pregnancy: reference intervals for before and after delivery." EBioMedicine vol. 74 (2021): 103715. doi: https://doi.org/10.1016/j.ebiom.2021.103715
Dockree S, Shine B, Pavord S, Impey L, Vatish M. White blood cells in pregnancy: reference intervals for before and after delivery. EBioMedicine. 2021 Nov 23;74:103715. doi: 10.1016/j.ebiom.2021.103715. Epub 2021 Nov 23. PMID: 34826802; PMCID: PMC8626574.
Copy Download .nbib Format: NLM
Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion.

The journal of allergy and clinical immunology. In practice

Buhl R, Bel E, Bourdin A, Dávila I, Douglass JA, FitzGerald JM, Jackson DJ, Lugogo NL, Matucci A, Pavord ID, Wechsler ME, Kraft M.
PMID: 34763123
J Allergy Clin Immunol Pract. 2021 Nov 08; doi: 10.1016/j.jaip.2021.10.059. Epub 2021 Nov 08.

Severe asthma often remains uncontrolled despite effective treatments and evidence-based guidelines. A group of global experts in asthma and biologic medications from 9 countries considered the most relevant clinical variables to manage severe asthma in adult patients and guide...

Cite
Buhl R, Bel E, Bourdin A, et al. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. J Allergy Clin Immunol Pract. 2021;doi: 10.1016/j.jaip.2021.10.059.
Buhl, R., Bel, E., Bourdin, A., Dávila, I., Douglass, J. A., FitzGerald, J. M., Jackson, D. J., Lugogo, N. L., Matucci, A., Pavord, I. D., Wechsler, M. E., & Kraft, M. (2021). Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. The journal of allergy and clinical immunology. In practice, . https://doi.org/10.1016/j.jaip.2021.10.059
Buhl, Roland, et al. "Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion." The journal of allergy and clinical immunology. In practice vol. (2021). doi: https://doi.org/10.1016/j.jaip.2021.10.059
Buhl R, Bel E, Bourdin A, Dávila I, Douglass JA, FitzGerald JM, Jackson DJ, Lugogo NL, Matucci A, Pavord ID, Wechsler ME, Kraft M. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. J Allergy Clin Immunol Pract. 2021 Nov 08; doi: 10.1016/j.jaip.2021.10.059. Epub 2021 Nov 08. PMID: 34763123.
Copy Download .nbib Format: NLM
Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience.

Pulmonary circulation

Albinni S, Pavo I, Kitzmueller E, Michel-Behnke I.
PMID: 33532055
Pulm Circ. 2021 Jan 20;11(1):2045894020979503. doi: 10.1177/2045894020979503. eCollection 2021.

Macitentan is a safe and effective substance for treatment of adults with pulmonary arterial hypertension. Data on its use in paediatric patients are limited. In this single-centre prospective study, we report on our experience with macitentan in children focusing...

Cite
Albinni S, Pavo I, Kitzmueller E, et al. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience. Pulm Circ. 2021;11(1):2045894020979503doi: 10.1177/2045894020979503.
Albinni, S., Pavo, I., Kitzmueller, E., & Michel-Behnke, I. (2021). Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience. Pulmonary circulation, 11(1), 2045894020979503. https://doi.org/10.1177/2045894020979503
Albinni, Sulaima, et al. "Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience." Pulmonary circulation vol. 11,1 (2021): 2045894020979503. doi: https://doi.org/10.1177/2045894020979503
Albinni S, Pavo I, Kitzmueller E, Michel-Behnke I. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience. Pulm Circ. 2021 Jan 20;11(1):2045894020979503. doi: 10.1177/2045894020979503. eCollection 2021. PMID: 33532055; PMCID: PMC7829536.
Copy Download .nbib Format: NLM
VITT and Second Doses of Covid-19 Vaccine.

The New England journal of medicine

Lacy J, Pavord S, Brown KE.
PMID: 34936738
N Engl J Med. 2022 Jan 06;386(1):95. doi: 10.1056/NEJMc2118507. Epub 2021 Dec 22.

No abstract available.

Cite
Lacy J, Pavord S, Brown KE. VITT and Second Doses of Covid-19 Vaccine. N Engl J Med. 2021;386(1):95doi: 10.1056/NEJMc2118507.
Lacy, J., Pavord, S., & Brown, K. E. (2022). VITT and Second Doses of Covid-19 Vaccine. The New England journal of medicine, 386(1), 95. https://doi.org/10.1056/NEJMc2118507
Lacy, Joanne, et al. "VITT and Second Doses of Covid-19 Vaccine." The New England journal of medicine vol. 386,1 (2022): 95. doi: https://doi.org/10.1056/NEJMc2118507
Lacy J, Pavord S, Brown KE. VITT and Second Doses of Covid-19 Vaccine. N Engl J Med. 2022 Jan 06;386(1):95. doi: 10.1056/NEJMc2118507. Epub 2021 Dec 22. PMID: 34936738.
Copy Download .nbib Format: NLM
Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes.

Lancet (London, England)

Bush A, Pavord ID.
PMID: 34656285
Lancet. 2021 Nov 20;398(10314):1856-1858. doi: 10.1016/S0140-6736(21)02244-3. Epub 2021 Oct 14.

No abstract available.

Cite
Bush A, Pavord ID. Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes. Lancet. 2021;398(10314):1856-1858doi: 10.1016/S0140-6736(21)02244-3.
Bush, A., & Pavord, I. D. (2021). Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes. Lancet (London, England), 398(10314), 1856-1858. https://doi.org/10.1016/S0140-6736(21)02244-3
Bush, Andy, and Pavord, Ian D. "Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes." Lancet (London, England) vol. 398,10314 (2021): 1856-1858. doi: https://doi.org/10.1016/S0140-6736(21)02244-3
Bush A, Pavord ID. Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes. Lancet. 2021 Nov 20;398(10314):1856-1858. doi: 10.1016/S0140-6736(21)02244-3. Epub 2021 Oct 14. PMID: 34656285.
Copy Download .nbib Format: NLM
The burden of exacerbations in mild asthma: a systematic review.

ERJ open research

FitzGerald JM, Barnes PJ, Chipps BE, Jenkins CR, O'Byrne PM, Pavord ID, Reddel HK.
PMID: 32802826
ERJ Open Res. 2020 Aug 11;6(3). doi: 10.1183/23120541.00359-2019. eCollection 2020 Jul.

BACKGROUND: Although most patients with asthma have mild disease, data on how mild asthma is defined, and how frequently exacerbations occur in this patient population are scarce, so we aimed to redress this.METHODS: We searched Medline and Medline In-Process...

Cite
FitzGerald JM, Barnes PJ, Chipps BE, et al. The burden of exacerbations in mild asthma: a systematic review. ERJ Open Res. 2020;6(3)doi: 10.1183/23120541.00359-2019.
FitzGerald, J. M., Barnes, P. J., Chipps, B. E., Jenkins, C. R., O'Byrne, P. M., Pavord, I. D., & Reddel, H. K. (2020). The burden of exacerbations in mild asthma: a systematic review. ERJ open research, 6(3), . https://doi.org/10.1183/23120541.00359-2019
FitzGerald, J Mark, et al. "The burden of exacerbations in mild asthma: a systematic review." ERJ open research vol. 6,3 (2020). doi: https://doi.org/10.1183/23120541.00359-2019
FitzGerald JM, Barnes PJ, Chipps BE, Jenkins CR, O'Byrne PM, Pavord ID, Reddel HK. The burden of exacerbations in mild asthma: a systematic review. ERJ Open Res. 2020 Aug 11;6(3). doi: 10.1183/23120541.00359-2019. eCollection 2020 Jul. PMID: 32802826; PMCID: PMC7418821.
Copy Download .nbib Format: NLM
Moving towards a Treatable Traits model of care for the management of obstructive airways diseases.

Respiratory medicine

Agusti A, Barnes N, Cruz AA, Gibson PG, Heaney LG, Inoue H, Leather D, Martinez FJ, McDonald VM, Oppenheimer J, Papi A, Pavord ID, Thomas M, Walker S, Yates L.
PMID: 34478992
Respir Med. 2021 Oct;187:106572. doi: 10.1016/j.rmed.2021.106572. Epub 2021 Aug 13.

Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent chronic airways diseases. Both are complex and heterogeneous. Traditionally, clinical guidelines have advocated a stepwise approach to pharmacotherapy of asthma and COPD, but there is increasing realization that both...

Cite
Agusti A, Barnes N, Cruz AA, et al. Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respir Med. 2021;187:106572doi: 10.1016/j.rmed.2021.106572.
Agusti, A., Barnes, N., Cruz, A. A., Gibson, P. G., Heaney, L. G., Inoue, H., Leather, D., Martinez, F. J., McDonald, V. M., Oppenheimer, J., Papi, A., Pavord, I. D., Thomas, M., Walker, S., & Yates, L. (2021). Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respiratory medicine, 187106572. https://doi.org/10.1016/j.rmed.2021.106572
Agusti, Alvar, et al. "Moving towards a Treatable Traits model of care for the management of obstructive airways diseases." Respiratory medicine vol. 187 (2021): 106572. doi: https://doi.org/10.1016/j.rmed.2021.106572
Agusti A, Barnes N, Cruz AA, Gibson PG, Heaney LG, Inoue H, Leather D, Martinez FJ, McDonald VM, Oppenheimer J, Papi A, Pavord ID, Thomas M, Walker S, Yates L. Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respir Med. 2021 Oct;187:106572. doi: 10.1016/j.rmed.2021.106572. Epub 2021 Aug 13. PMID: 34478992.
Copy Download .nbib Format: NLM
Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease.

Breathe (Sheffield, England)

Bush A, Pavord ID.
PMID: 35035544
Breathe (Sheff). 2021 Sep;17(3):210053. doi: 10.1183/20734735.0053-2021.

Airway diseases were initially described by nonspecific patterns of symptoms, for example "dry and wheezy" and "wet and crackly". The model airway disease is cystic fibrosis, which has progressed from nonspecific reactive treatments such as antibiotics for airway infection...

Cite
Bush A, Pavord ID. Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease. Breathe (Sheff). 2021;17(3):210053doi: 10.1183/20734735.0053-2021.
Bush, A., & Pavord, I. D. (2021). Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease. Breathe (Sheffield, England), 17(3), 210053. https://doi.org/10.1183/20734735.0053-2021
Bush, Andrew, and Pavord, Ian D. "Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease." Breathe (Sheffield, England) vol. 17,3 (2021): 210053. doi: https://doi.org/10.1183/20734735.0053-2021
Bush A, Pavord ID. Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease. Breathe (Sheff). 2021 Sep;17(3):210053. doi: 10.1183/20734735.0053-2021. PMID: 35035544; PMCID: PMC8753662.
Copy Download .nbib Format: NLM
A quality improvement project for the cost-effective management of maternal anaemia.

British journal of haematology

Colman KS, Pavord S, Roy N.
PMID: 34462912
Br J Haematol. 2021 Aug 31; doi: 10.1111/bjh.17797. Epub 2021 Aug 31.

No abstract available.

Cite
Colman KS, Pavord S, Roy N. A quality improvement project for the cost-effective management of maternal anaemia. Br J Haematol. 2021;doi: 10.1111/bjh.17797.
Colman, K. S., Pavord, S., & Roy, N. (2021). A quality improvement project for the cost-effective management of maternal anaemia. British journal of haematology, . https://doi.org/10.1111/bjh.17797
Colman, Katherine S, et al. "A quality improvement project for the cost-effective management of maternal anaemia." British journal of haematology vol. (2021). doi: https://doi.org/10.1111/bjh.17797
Colman KS, Pavord S, Roy N. A quality improvement project for the cost-effective management of maternal anaemia. Br J Haematol. 2021 Aug 31; doi: 10.1111/bjh.17797. Epub 2021 Aug 31. PMID: 34462912.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 127 entries